WaveMan
WaveMan · Company
ORGO · Organogenesis Holdings Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ORGO Organogenesis (ORGO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001661181
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
86
13F, latest reported quarter

Organogenesis insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Organogenesis Holdings Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Leibowitz Arthur S
Director
BUY
2026-03-11 SECtraded 2026-03-09
5,000
$13.4K
-64.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 12, 2022.
  • The trade is 1.7% of the 291,014 shares held after it.
  • 1 other insider bought within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Leibowitz Arthur S bought about $13.4K of ORGO on Mar 9, 2026; 1 other insider bought within 30 days and 86 funds added in the latest 13F quarter.
Driscoll Michael Joseph
Director
BUY
2026-03-11 SECtraded 2026-03-09
10,000
$26.7K
-64.7%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Mar 4, 2025.
  • The trade is 4.4% of the 225,707 shares held after it.
  • 1 other insider bought within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Driscoll Michael Joseph bought about $26.7K of ORGO on Mar 9, 2026; 1 other insider bought within 30 days and 86 funds added in the latest 13F quarter.
NUSSDORF GLENN H
Director
SELL
2025-12-18 SECtraded 2025-12-16
200,000
$1.0M
-83.3%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (2 buys, 5 sales), the last on Nov 26, 2025.
  • +62.3% median (+62.3% mean) 90-day return after 2 previous buys.
  • The trade is 7.8% of the 2,565,591 shares held after it.
  • No other insider sold within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director NUSSDORF GLENN H sold about $1.0M of ORGO on Dec 16, 2025, the largest insider sale at the company since 2021; 86 funds added in the latest 13F quarter.
NUSSDORF GLENN H
Director
SELL
2025-11-26 SEC
187,957
$994.3K
-81.9%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (2 buys, 4 sales), the last on Nov 25, 2025.
  • +62.3% median (+62.3% mean) 90-day return after 2 previous buys.
  • The trade is 6.8% of the 2,765,591 shares held after it.
  • No other insider sold within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director NUSSDORF GLENN H sold about $994.3K of ORGO on Nov 26, 2025, the largest insider sale at the company since 2021; 86 funds added in the latest 13F quarter.
NUSSDORF GLENN H
Director
SELL
2025-11-26 SECtraded 2025-11-25
12,043
$63.8K
-81.9%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (2 buys, 3 sales), the last on Nov 24, 2025.
  • +62.3% median (+62.3% mean) 90-day return after 2 previous buys.
  • The trade is 0.4% of the 2,953,548 shares held after it.
  • No other insider sold within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director NUSSDORF GLENN H sold about $63.8K of ORGO on Nov 25, 2025; 86 funds added in the latest 13F quarter.
80 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 75 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
86 funds bought in last quarter
more than 63% of Pharma & Biotech
Revenue
+17.0% year over year
more than 64% of Pharma & Biotech
Margin
6.6% net margin
more than 77% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
24.6% of the float short (float per yahoo 2026-10-26) · 26.6 days to cover · settled 2026-09-30
more than 77% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ORGO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-77.3%12M
-77%-32%+14%+59%2025-102025-122026-022026-042026-062026-082026-10 2025-12-16 · NUSSDORF GLENN H sold $1.0M2025-11-26 · NUSSDORF GLENN H sold $994.3K2025-11-24 · NUSSDORF GLENN H sold $534.0K2025-11-25 · NUSSDORF GLENN H sold $63.8K2026-03-09 · Driscoll Michael Joseph bought $26.7K2026-03-09 · Leibowitz Arthur S bought $13.4K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ORGO: institutional holders (13F)

13F holdings, latest reported quarter
MORGAN STANLEY
11,721,609 sh
$28.5M
Soleus Capital Management, L.P.
10,140,951 sh
$24.6M
BlackRock, Inc.
7,249,528 sh
$17.6M
Assenagon Asset Management S.A.
3,935,904 sh
$9.6M
DIMENSIONAL FUND ADVISORS LP
3,050,297 sh
$7.4M

Congress trades in ORGO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ORGO planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ORGO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Voya MI Dynamic SMID Cap Fund
$477.9K position · as of 2026-05-31
0.3%
Schwab Small-Cap Equity Fund
$809.7K position · as of 2026-07-31
0.1%
SIIT SMALL CAP FUND
$146.5K position · as of 2026-05-31
0.1%
GuideMark Small/Mid Cap Core Fund
$75.0K position · as of 2026-06-30
0.1%
BlackRock Advantage Small Cap Growth Fund
$458.6K position · as of 2026-06-30
0.1%
Clearwater Select Equity Fund
$231.6K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Gary S. Gillheeney, Sr.
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.8M
$15.2M
$2.1M
-31%
+20%
2024
$7.0M
$12.5M
$2.1M
-33%
+14%
2023
$6.2M
$10.5M
$1.9M
-15%
+15%
2022
$6.0M
-$1.0M
$1.3M
-44%
+11%
2021
$4.4M
$6.3M
$1.3M
+92%
+25%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 86 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ORGO financials

Revenue growth
+17.0%
XBRL, annual
Net margin
6.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$457.5M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-18.4%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$20.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.42x
long-term debt only, 2024-09-30 (21 months older than the period end); equity 2026-06-30
Cash flow to debt
0.51x
TTM operating cash flow over long-term debt only, 2024-09-30 (21 months older than the period end)
Return on equity
-44.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-19.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-9.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$136.6M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term debt only, 2024-09-30 (21 months older than the period end), minus cash 2026-06-30
FCF yield
+17.3%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$564.2M$482.0M$433.1M$450.9M
Gross profitn/a$366.3M$326.7M$345.9M
Operating income$44.7M-$1.3M$12.5M$22.3M
Net income$37.0M$900.0K$4.9M$15.5M
EPS (diluted)0.15-0.010.040.12
Operating cash flow-$10.3M$14.2M$30.9M$24.9M
Cash$93.7M$135.6M$103.8M$102.5M
Long-term debtn/an/a$66.6M$71.2M
Buybacksn/a$25.5M$0$0
SEC XBRL, fiscal years, as known on 2026-10-28

ORGO Stock Sonar score 5/7 axes

Find similar shapesCompare

ORGO ranks highest on profitability (68th percentile) and growth (64th), and lowest on risk and compliance (32nd), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
68
Inputs
  • Return on equity-44.1% · 58 pct, sector of 545
  • Return on assets-19.4% · 67 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-9.6% · 79 pct, sector of 576
Financial health
62
Inputs
  • Debt to equity0.42x · 35 pct, sector of 352
  • Cash flow to debt0.51x · 88 pct, sector of 371
Growth
64
Inputs
  • Revenue growth, YoY+17.0% · 64 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
63
Inputs
  • Funds adding, latest quarter86 · 63 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
32
Inputs
  • Short interest, % of float+24.6% · 8 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+9.6% · 55 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies